Farmacy

Jan 7 2018

UCB to buy Schwarz Pharma for $5 #biotech #company

#schwarz pharma # UCB to buy Schwarz Pharma for $5.6 billion LONDON (MarketWatch) — Belgium’s UCB on Monday said it agreed to pay $5.6 billion for Germany’s Schwarz Pharma, the third multibillion-dollar takeover in the European pharmaceutical industry in the past five days. UCB (000373953) said it’s paying 4.4 billion euros in cash and shares, representing a 20% premium to Friday’s close, for Schwarz Pharma (722190). The deal follows proposals by Germany’s Merck KGaA (659990) to buy Switzerland’s Serono SRA, +0.00% for $13.3 billion, and Denmark’s Nycomed to buy the pharmaceutical operations of Germany’s Altana AAA, +8.70% for $5.8 billion. …

Jan 7 2018

Actavis to Buy Forest Laboratories for $25 Billion #penn #pharma

#forest pharma # Actavis to Buy Forest Laboratories for $25 Billion Actavis Plc, the world’s second-largest generic-drug maker by market value, agreed to buy Forest Laboratories Inc. for about $25 billion in a deal that will transform it into a developer of brand-name drugs. The deal is a win for billionaire investor Carl Icahn, Forest’s second-largest holder who gained seats on the company’s board in 2012 and 2013, and pushed for a sale. Forest investors will get cash and stock valued at $89.48 a share, based on the Feb. 14 closing price, the companies said today in a statement. The …

Jan 7 2018

Teva to buy Barr Pharma for more than $7b #hra #pharma

#barr pharma #from the September 2008 issue Teva to buy Barr Pharma for more than $7b. Teva Pharmaceutical confirmed its purchase of rival generic drugmaker Barr Pharmaceuticals for nearly $7.5 billion in a move that will boost Teva’s dominance as the world’s largest generic drugmaker. The deal continues consolidation of the generic-drug sector, driven by growth prospects as governments and other payers turn to the lower-priced medications and by the impending expiration of brand-name drug patents worth billions of dollars a year. Israel-based Teva Pharmaceutical Industries Ltd. said acquiring Montvale, N.J.-based Barr Pharmaceuticals Inc. the world’s No. 4 generic drug …

Jan 7 2018

Sun Pharma to buy Dusa for $230 million #schwarz #pharma

#dusa pharma # Sun Pharma to buy Dusa for $230 million Updated: Thu, Nov 08 2012. 11 43 PM IST Mumbai: Sun Pharmaceuticals Industries Ltd. India s most valuable drug maker, has agreed to buy US-based skincare speciality company DUSA Pharmaceuticals Inc. for $230 million ( Rs. 1,251 crore). Under the terms of the agreement, a subsidiary of Sun Pharma will commence a tender offer for all outstanding common stock of DUSA at a price of $8 per share in cash, a 38% premium to the closing price on 7 November, the Indian company said on Thursday. The transaction has …

Jan 7 2018

Amgen to Buy Onyx for $10 #pharma #headhunters

#onyx pharma # Amgen to Buy Onyx for $10.4 Billion to Gain Cancer Drug Amgen Inc. agreed to buy Onyx Pharmaceuticals Inc. in a $10.4 billion transaction that gives Amgen access to a rapidly expanding cancer-drug market with a new product that offers sure revenue. Amgen will pay $125 a share for Onyx’s outstanding stock, the companies said in a statement yesterday. Net of estimated Onyx cash, the deal is worth $9.7 billion. Onyx’s Kyprolis, approved last year for a rare blood cancer, may spur more than $3 billion in revenue by 2021, according to analyst estimates compiled by Bloomberg. …

Dec 25 2017

Pharmacom Labs Worldwide Official Distributor since 2008 – Buy Here #esai #pharma

#pharma.com # PULSE Trenbolone for the Very First Steroid Cycle Q: Your articles have two pieces of advice that are totally contrary to recommendations I read on boards everywhere. One, even for a guy s very first cycle you seem to like choosing trenbolone. Everywhere else, the vets shoot that down when anyone suggests that s what they want to do for a first cycle. You also write cycles up around a gram per week for first cycles. Same thing. Are those old recommendations which you ve since changed, or is there a reason behind them? A: I still often …

Dec 22 2017

3 High-Dividend Pharmaceutical Stocks to Buy #pharmaceutical #contract #manufacturer

#pharma stocks # 3 High-Dividend Pharmaceutical Stocks to Buy NEW YORK (TheStreet ) — With Eli Lilly Co. (LLY ) experimenting with a new drug for Alzheimer’s disease, we decided to check Quant Ratings for pharmaceutical stocks to buy. The companies we chose also pay high dividends. Eli Lilly taking a risk on this new drug is nothing new to the industry. The sector is full of risks: Drugs in development might flop; the FDA might not approve them, and even if they are approved, there’s a chance those drugs won’t sell. That said, there are benefits from investing in …

Dec 9 2017

Dublin-based Actavis to buy Forest Labs for $25 billion #pharma #sales #jobs

#forest pharma # Dublin-based Actavis to buy Forest Labs for $25 billion Actavis. the world’s second-largest generic-drug maker by market value, is to buy Forest Laboratories in a cash and stock deal valued at about $25 billion. Actavis will pay the equivalent of $89.48 per share, representing a premium of 25 per cent to Forest’s Friday close. The offer comprises $26.04 in cash and 0.3306 Actavis shares for every Forest share. Forest had a market value of $19.3 billion at the close of trading last Friday. Dublin-headquartered Actavis was the most active buyer of drug companies over the past three …

Dec 8 2017

UCB to buy Schwarz Pharma for $5 #leading #pharmaceutical #companies #2013

#schwarz pharma # UCB to buy Schwarz Pharma for $5.6 billion LONDON (MarketWatch) — Belgium’s UCB on Monday said it agreed to pay $5.6 billion for Germany’s Schwarz Pharma, the third multibillion-dollar takeover in the European pharmaceutical industry in the past five days. UCB (000373953) said it’s paying 4.4 billion euros in cash and shares, representing a 20% premium to Friday’s close, for Schwarz Pharma (722190). The deal follows proposals by Germany’s Merck KGaA (659990) to buy Switzerland’s Serono SRA, +0.00% for $13.3 billion, and Denmark’s Nycomed to buy the pharmaceutical operations of Germany’s Altana AAA, +8.70% for $5.8 billion. …

Dec 8 2017

Sun Pharma inks pact to buy DUSA for $230 million – The Hindu #pharma #etf

#dusa pharma # Sun Pharma inks pact to buy DUSA for $230 million Sun Pharmaceutical Industries, on Thursday, said it had inked a pact to acquire U.S.-based DUSA Pharmaceuticals for around $230 million (about Rs.1,250 crore). Sun Pharma and DUSA Pharmaceuticals have entered into a definitive agreement under which Sun Pharma will acquire DUSA, a dermatology company focused on developing and marketing its Levulan photo-dynamic therapy platform, Sun Pharma said in a statement. Under the terms of the agreement, a 100 per cent subsidiary of Sun Pharma will commence a tender offer for all of the outstanding common stock of …